• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6,368
2,300
1,860
1,850
1,725

COUNTRY

867
650
270
253
211

CATEGORIES

  • 858
  • 186
  • 679
  • 1,126
  • 391
  • 270
  • 253
  • 65
  • 378
  • 693
  • 1,330
  • 1,355
  • 625
  • 884
  • 1,695
  • 2,677
  • 507
  • 732
  • 0
  • 93

PRICE

6,806
11,420
17,965
25,170

PUBLISHED

1,890
2,637
7,230
25,170

PRODUCT TYPE

21,047
2,901
871
164
75
44
21
21
19
6
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE

PharmaPoint: Psoriasis - Italy Drug Forecast and Market Analysis to 2022

PharmaPoint: Psoriasis - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - Italy Drug Forecast and Market Analysis to...

May 2013
FROM

PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022

PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The...

May 2013
FROM

Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute...

May 2013
FROM

PharmaPoint: Dry Eye Syndrome - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Dry Eye Syndrome - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - Japan Drug Forecast and Market...

May 2013
FROM

PharmaPoint: Dry Eye Syndrome - Current and Future Players

PharmaPoint: Dry Eye Syndrome - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Dry Eye Syndrome - Current and Future Players”. The report is a vital source...

May 2013
FROM

Simeprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Simeprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation....

May 2013
FROM

PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022 Summary Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized...

May 2013
FROM

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation...

May 2013
FROM

PharmaPoint: Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2022

Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation DES, which is often referred...

May 2013
FROM

Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results...

May 2013
FROM

PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market...

May 2013
FROM

Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic...

May 2013
FROM

PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and...

May 2013
FROM
ICT Spend Predictions in Small Belgian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013 ICT Spend Predictions in Small Belgian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013 - Product Thumbnail Image

ICT Spend Predictions in Small Belgian Pharmaceutical Companies - Estimated ICT budget breakdowns in 2013

Synopsis This report illustrates how Kable expects Pharmaceutical to allocate their ICT budgets across the core areas of enterprise ICT spend, namely hardware, software, IT services, telecommunications...

May 2013
FROM

China Pharmaceutical Raw Materials Mfg. Industry Profile - CIC2710

Through a comparative analysis on the development of pharmaceutical raw materials mfg. industry in 31 provincial regions and 20 major cities in visualized form of data map, the report provides key data...

May 2013
FROM

China Pharmaceutical Mfg. Industry Profile - CIC27

Through a comparative analysis on the development of pharmaceutical mfg. industry in 31 provincial regions and 20 major cities in visualized form of data map, the report provides key data and concise...

May 2013
FROM

PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022

PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to...

May 2013
FROM

Stelara (Psoriasis) - Forecast and Market Analysis to 2022

Stelara (Psoriasis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Stelara (Psoriasis) - Forecast and Market Analysis to 2022”....

May 2013
FROM

Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022

Ixekizumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2–3% worldwide...

May 2013
FROM

Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022

Xeljanz (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2–3% worldwide...

May 2013
FROM
Loading Indicator

Our Clients

Our clients' logos